Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2025

Genmab — Oktober 2025

Planlagt Fastgjort Låst Flyttet Genmab
427 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #323

    Petosemtamab er allerede i fase 3 over for netop hoved- og halskræft. Merus er færd med to fase 3-studier i kræftformen som henholdsvis førstebehandling og anden/tredjebehandling. Resultater fra et eller måske begge fase 3-studier ventes næste år.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #324

      Good move by Genmab to proceed this fast with the tender offer, confirming they have no doubts about their offer. After all, very theoretically, Genmab could decide NOT to pursue the transaction if they felt they had done something really really stupid. It would cost them over $400 million in termination fees -and their reputation- but in theory i guess it is possible...

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #325

        And we should not forget that Genmab was not the only bidder; there was (at least) 1 party interested in partnering Peto, and there were (at least?) 2 parties bidding at a price very close to the $97 Genmab ended up paying... and these had done the same due diligence

        1 Reply Last reply
        0
        • W Offline
          W Offline
          w
          wrote on sidst redigeret af
          #326

          virker lidt som drilleri at JJ kun viser HPV negative resultater.

          1 Reply Last reply
          0
          • J Offline
            J Offline
            JKY_VH
            wrote on sidst redigeret af
            #327

            God pointe E L 15:13

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #328

              @w Det var resultatet fra cohort 1 ud af 4. Så de har næppe flere færdige resultater.

              1 Reply Last reply
              0
              • SolsenS Offline
                SolsenS Offline
                Solsen
                wrote on sidst redigeret af
                #329

                Ligner til at markedet er faldet til ro 😉

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #330

                  Amivantamab resultatet vil hjælpe med til, at Genmab kan få opkøbt de sidste aktier i Merus - lidt glæde får vi trods alt af det 😉

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #331

                    tisotumab isn't the only ADC with toxicity challenges https://x.com/Dr_Oncologista/status/1980617077204390285/photo/2

                    1 Reply Last reply
                    0
                    • N Offline
                      N Offline
                      NiklasZ
                      wrote on sidst redigeret af
                      #332

                      Det passer med en wave 4 korrektion ABC til at lukke gap medio november og derefter op i wave 5.

                      1 Reply Last reply
                      0
                      • concilladoC Offline
                        concilladoC Offline
                        concillado
                        wrote on sidst redigeret af
                        #333

                        Det lader til at kursen er stabiliseret på det amerikanske marked. Lad os se om der fortsat sælges ud i morgen. Eller om turen skal op igen 🙂

                        1 Reply Last reply
                        0
                        • StockBullS Offline
                          StockBullS Offline
                          StockBull
                          wrote on sidst redigeret af
                          #334

                          god morgen 🙂 Ja, en retracement frem til 10.-15. november synes sandsynligt, baseret på de seneste retracements, som typisk har udgjort omkring fire lys ned på ugekortet.

                          1 Reply Last reply
                          0
                          • T Offline
                            T Offline
                            Tudekiksen
                            wrote on sidst redigeret af
                            #335

                            Ny i Genmab - købte i går i kurs 1886.

                            1 Reply Last reply
                            0
                            • T Offline
                              T Offline
                              Tudekiksen
                              wrote on sidst redigeret af
                              #336

                              Sikker trættende spørgsmål: Aktiesplit

                              1 Reply Last reply
                              0
                              • T Offline
                                T Offline
                                Tudekiksen
                                wrote on sidst redigeret af
                                #337

                                Er det i spil?

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bibob
                                  wrote on sidst redigeret af
                                  #338

                                  @tudekiksen. Nok ikke i Genmab.

                                  1 Reply Last reply
                                  0
                                  • T Offline
                                    T Offline
                                    Tudekiksen
                                    wrote on sidst redigeret af
                                    #339

                                    @bibob Tak for svar. Kunne jo være man ville splitte 1 til 10... Men det er altså ikke på tale... 🙂

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #340

                                      In a report released yesterday, Michael Schmidt from Guggenheim reiterated a
                                      Buy rating on Genmab, with a price target of $45.00 https://www.theglobeandmail.com/investing/markets/stocks/GMAB-Q/pressreleases/35581001/guggenheim-sticks-to-their-buy-rating-for-genmab-gmab/

                                      1 Reply Last reply
                                      0
                                      • J Offline
                                        J Offline
                                        JKY_VH
                                        wrote on sidst redigeret af
                                        #341

                                        tak E L, Michael Schmidt må også kende JnJ-data og ryster alligevel ikke i bukserne:-)

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #342

                                          yes, 4 analysts, Guggenheim , Wainwright ,Truist and Blair kept their hold and target after ESMO so hopefully that gives a bit of confidence

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper